Clinical trial
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
NCT04439253
Study timeline
Study start (actual)2015-08-12Date precision: day
Registry last updated2026-09-18
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Advanced Lymphomaunresolved
Advanced Malignant Solid Neoplasmunresolved
Hematopoietic and Lymphoid Cell Neoplasmunresolved
Refractory Lymphomaunresolved
Refractory Malignant Solid Neoplasmunresolved
Refractory Multiple Myelomaunresolved
Interventions
CrizotinibDRUG · verified · RxNorm: crizotinib
Sponsors & collaborators
National Cancer Institute (NCI)lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04439253 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.